• Pazopanib (GW-786034) in ATRX-Deficient Glioma

  2026-08-14

  Pazopanib (GW-786034) enables a genotype-aware workflow for studying receptor tyrosine kinase dependence, angiogenesis inhibition, and tumor growth suppression. This guide connects ATRX-deficient glioma findings with practical dose-response, signaling, combination, and troubleshooting strategies for reproducible cancer research.

• Dorsomorphin 2HCl: AMPK Inhibitor Workflows

  2026-08-14

  Dorsomorphin 2HCl helps separate AMPK-dependent metabolic effects from probiotic or nutrient interventions in liver models while also enabling BMP pathway and osteogenesis studies. This practical guide covers solvent handling, assay design, pathway-specific readouts, and troubleshooting for more interpretable preclinical experiments.

• Urolithin A: Mitochondrial Quality Control

  2026-08-13

  Urolithin A is a gut microbiota-derived metabolite studied as a mitophagy activator for mitochondrial quality control. Preclinical and human studies support research into mitochondrial function and skeletal muscle mitochondrial gene expression modulation, but they do not establish broad clinical efficacy.

• Pentoxifylline Workflows for Inflammation Research

  2026-08-13

  Pentoxifylline connects cAMP-centered phosphodiesterase inhibition with practical inflammation, infection, psoriasis, and sperm-motility assays. This workflow-focused guide covers concentration selection, endpoint design, cross-domain limitations, and troubleshooting for more reproducible results.

• Lambda Protein Phosphatase for BMAL1 Studies

  2026-08-12

  Use Lambda Protein Phosphatase to separate phosphorylation-dependent effects from protein abundance, antibody binding, and condensate formation. This workflow applies λ-PPase to BMAL1 phase-separation experiments, phospho-specific antibody validation, and functional protein assays with defined Mn²⁺-dependent reaction conditions.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-08-12

  Chen et al. integrated carbapenemase-gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element profiling, and ERIC-PCR to characterize resistant Enterobacter cloacae across eight Guangdong teaching hospitals. The study identifies plasmid-associated blaNDM-1 and efficient horizontal transfer as central surveillance priorities, while also showing that clonally related strains can circulate across departments and institutions.

• Trichostatin A: Designing Better HDAC Assays

  2026-08-11

  Trichostatin A (TSA) is more than a broad HDAC inhibitor: it is a controllable probe for linking histone acetylation to cell-state and metabolic phenotypes. This guide translates cancer and dendritic-cell evidence into better assay-design decisions, with attention to dose, exposure, solvent, and interpretation.

• GW 4869 for Exosome and Ceramide Studies

  2026-08-11

  GW 4869 helps separate neutral sphingomyelinase-dependent vesicle release from downstream recipient-cell signaling. This practical guide applies GW 4869 hydrochloride hydrate to BMSC exosome studies inspired by lithium-enhanced osteogenesis, with dose-planning, controls, and troubleshooting strategies for cleaner mechanistic conclusions.

• Vidarabine monohydrate: Assay Workflows

  2026-08-10

  Build reproducible antiviral assays around Vidarabine monohydrate with DMSO-first formulation, orthogonal viral readouts, and controls that separate DNA replication interference from cytotoxicity. The workflow is tailored to herpes simplex virus research while adapting a screening-and-validation principle from a distinct 2025 molecular pharmacology study.

• Dextrose in Hypoxia and Immunometabolism Research

  2026-08-09

  Dextrose (D-glucose) gives researchers a controllable nutrient variable for modeling glycolysis, tumor hypoxia, immune-cell competition, and cellular energy production. This practical guide translates immunometabolism concepts into reproducible media preparation, oxygen–glucose experiments, assay controls, and troubleshooting decisions.

• Ro 3306: Selective CDK1 Inhibitor Guide

  2026-08-08

  Ro 3306 is an ATP-competitive CDK1 inhibitor that targets CDK1/cyclin B1 and CDK1/cyclin A, producing a controllable G2/M block. Its value extends from cancer cell synchronization to DNA repair mechanism study, but Ki values, cellular responses, and DNA repair phenotypes require separate interpretation.

• A20, Oxidized Self-DNA, and AKI Inflammation

  2026-08-07

  The reference study identifies oxidized self-DNA as a driver of acute kidney injury through coordinated cGAS–STING signaling and NLRP3 inflammasome activation. It further shows that A20 and an A20-derived peptide suppress NEK7-dependent pyroptosis, providing a mechanistic basis for future AKI interventions.

• Cefiderocol Efficacy Against Resistant European Enterobacter

  2026-08-07

  The referenced study systematically evaluated cefiderocol's in vitro activity against a large collection of European Enterobacterales, including strains resistant to meropenem and advanced β-lactam/β-lactamase inhibitor combinations. Its findings highlight cefiderocol as a highly active single-agent option for multidrug-resistant isolates, underscoring the need for early susceptibility testing in clinical microbiology workflows.

• Amyloid Beta-peptide (25-35): Microglial Dynamics & AD Pathw

  2026-08-06

  Explore the role of Amyloid Beta-peptide (25-35) in dissecting microglial polarization and neuroinflammation in Alzheimer's disease models. This in-depth article reveals novel mechanistic insights and practical assay guidance for advanced neurodegenerative disease research.

• MK-8745, Aurora A Inhibitor: Enhancing Cell Cycle & Apoptosi

  2026-08-06

  This article explores how MK-8745, Aurora A inhibitor, potent and selective (SKU A8807), addresses persistent challenges in cell viability, proliferation, and cytotoxicity assays. Through scenario-driven Q&A, we demonstrate its data-backed value for reproducibility, sensitivity, and workflow optimization in cancer research.

16047 records 1/1070 page Next 12345 下5页 Last page